Current status and future perspectives of multi-modal bacteria-based cancer therapies

Abstract

Background: Targeted drug delivery systems have garnered increasing research interest in cancer threapy. Bacteria have emerged as a promising vehicle due to their innate ability to the tumour microenvironment (TME) and their intrinsic immune-stimulating properties. This review explores the application of bacteria in oncology, emphasizing the tumour-targeting behaviour of specific strains, their immunomodulatory functions, and their potential as delivery platforms for the controlled release of therapeutic agents.

Main text: This review synthesizes recent advances in bacteria-mediated cancer therapy, focusing on the mechanisms underlying bacterial targeting of hypoxic and immunosuppressive regions within the tumor microenvironment (TME). We discuss how genetic modification has been employed to design recombinant bacterial strains with enhanced tumor specificity and amplified therapeutic effects. Furthermore, the integration of bacteria with nanotechnology has facilitated the development of hybrid systems capable of targeted drug delivery and triggered-release mechanisms. The combination of bacterial therapy with other treatment modalities—such as photodynamic (PDT) and sonodynamic therapies (SDT)—is also examined, emphasizing their synergistic potential in overcoming tumor heterogeneity and enhancing anti-tumor immunity. Finally, we survey the current clinical progress of bacteria-based therapeutics and offer perspectives on the future role of artificial intelligence (AI) in improving the design and application of these living medicines.

Conclusions: Bacteria-based delivery systems represent a multifunctional and innovative strategy in the evolution of targeted cancer therapies. Through genetic modification and nanobiotechnology approaches, bacteria can be customized to mediate multi-effect synergistic treatments for cancer, enhancing the precision, safety, and efficacy of cancer therapies. With the ongoing integration of advanced technologies, including AI, there is great potential to overcome existing limitations and accelerate the clinical translation of bacterial anticancer therapies. This interdisciplinary effort is poised to open new avenues for next-generation cancer treatments and lay the foundation for future directions in cancer research and therapeutic practice.

Keywords

bacteria / cancer / TME / genetic modification / nanotechnology / synergistic therapy

References

[1] Chen Z, Yuan Y, Chen X, et al. Systematic comparison of somatic variant calling performance among different sequencing depth and mutation frequency. Sci Rep. 2020; 10(1): 3501.

[2] Xia T, Zhu R. Multiple molecular and cellular mechanisms of the antitumour effect of dihydromyricetin (review). Biomed Rep. 2024; 20(5): 82.

[3] Longley D, Harkin D, Johnston P. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003; 3(5): 330-338.

[4] Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991; 21(1): 109-122.

[5] Moghimipour E, Abedishirehjin S, Baghbadorani MA, Handali S. Bacteria and archaea: a new era of cancer therapy. J Control Release. 2021; 338: 1-7.

[6] Chiang C, Hong Y. In situ delivery of biobutyrate by probiotic Escherichia coli for cancer therapy. Sci Rep. 2021; 11(1): 18172.

[7] Kamat AM, Colombel M, Sundi D, et al. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol. 2017; 14(4): 244-255.

[8] Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, et al. Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: a randomized, placebo-controlled, phase 1 trial. Oncoimmunology. 2015; 4(4): e1001217.

[9] Martel S, Felfoul O, Mohammadi M, Mathieu JB. Interventional procedure based on nanorobots propelled and steered by flagellated magnetotactic bacteria for direct targeting of tumors in the human body. Annu Int Conf IEEE Eng Med Biol Soc. 2008; 2008: 2497-2500

[10] Zong R, Ruan H, Liu C, Fan S, Li J. Bacteria and bacterial components as natural bio-nanocarriers for drug and gene delivery systems in cancer therapy. Pharmaceutics. 2023; 15(10): 2490.

[11] Sfanos K. Intratumoral bacteria as mediators of cancer immunotherapy response. Cancer Res. 2023; 83(18): 2985-2986.

[12] Coley W. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Clin Orthop Relat Res. 1893; 1991(262): 3-11.

[13] Janku F, Zhang HH, Pezeshki A, et al. Intratumoral injection of Clostridium novyi-NT spores in patients with treatment-refractory advanced solid tumors. Clin Cancer Res. 2021; 27(1): 96-106.

[14] Harimoto T, Danino T. Engineering bacteria for cancer therapy. Emerg Top Life Sci. 2019; 3(5): 623-629.

[15] Leschner S, Westphal K, Dietrich N, et al. Tumor invasion of Salmonella enterica serovar Typhimurium is accompanied by strong hemorrhage promoted by TNF-alpha. PLoS ONE. 2009; 4(8): e6692.

[16] Zhang Y, Ji W, He L, et al. E. coli Nissle 1917-derived minicells for targeted delivery of chemotherapeutic drug to hypoxic regions for cancer therapy. Theranostics. 2018; 8(6): 1690-1705.

[17] Fu S, Zhang R, Gao Y, et al. Programming the lifestyles of engineered bacteria for cancer therapy. Natl Sci Rev. 2023; 10(5): nwad031.

[18] Harimoto T, Hahn J, Chen Y, et al. A programmable encapsulation system improves delivery of therapeutic bacteria in mice. Nat Biotechnol. 2022; 40(8): 1259-1269.

[19] Duong MT, Qin Y, You S, Min J. Bacteria-cancer interactions: bacteria-based cancer therapy. Exp Mol Med. 2019; 51(12): 1-15.

[20] Hu H, Zhao J, Ma K, et al. Sonodynamic therapy combined with phototherapy: novel synergistic strategy with superior efficacy for antitumor and antiinfection therapy. J Control Release. 2023; 359: 188-205.

[21] Lou X, Chen Z, He Z, Sun M, Sun J. Bacteria-mediated synergistic cancer therapy: small microbiome has a big hope. Nano-Micro Lett. 2021; 13(1): 37.

[22] Van Dessel N, Swofford C, Forbes N. Potent and tumor specific: arming bacteria with therapeutic proteins. Therapeutic Deliv. 2015; 6: 385-399.

[23] Bubnovskaya L, Osinsky D. Tumor microenvironment and metabolic factors: contribution to gastric cancer. Exp Oncol. 2020; 42(1): 2-10.

[24] Li Y, Zhao L, Li X. Hypoxia and the tumor microenvironment. Technol Cancer Res Treat. 2021; 20: 15330338211036304.

[25] Gordan J, Thompson C, Simon M. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell. 2007; 12(2): 108-113.

[26] Pawelek J, Low K, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 1997; 57(20): 4537-4544.

[27] Feng X, He P, Zeng C, et al. Novel insights into the role of Clostridium novyi-NT related combination bacteriolytic therapy in solid tumors. Oncol Lett. 2021; 21(2): 110.

[28] Lin D, Feng X, Mai B, et al. Bacterial-based cancer therapy: an emerging toolbox for targeted drug/gene delivery. Biomaterials. 2021; 277: 121124.

[29] Al-Saafeen B, Fernandez-Cabezudo M, Al-Ramadi B. Integration of Salmonella into combination cancer therapy. Cancers (Basel). 2021(13): 13.

[30] Roy S, Kumaravel S, Sharma A, Duran CL, Bayless KJ, Chakraborty S. Hypoxic tumor microenvironment: implications for cancer therapy. Exp Biol Med. 2020; 245: 153537022093403.

[31] Wall D, Srikanth C, McCormick B. Targeting tumors with Salmonella Typhimurium- potential for therapy. Oncotarget. 2010; 1(8): 721-728.

[32] Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci. 2001; 98(26): 15155-15160.

[33] Rodríguez JM, Murphy K, Stanton C, et al. The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis. 2015; 26: 26050.

[34] Xu K, ed. Tumor Angiogenesis and Modulators. IntechOpen; 2022.

[35] Ebadi Sharafabad B, Abdoli A, Panahi M, et al. Anti-tumor effects of cisplatin synergist in combined treatment with Clostridium novyi-NT spores against hypoxic microenvironments in a mouse model of cervical cancer caused by TC-1 cell line. Adv Pharm Bull. 2023; 13(4): 817-826.

[36] Torres W, Lameda V, Olivar LC, et al. Bacteria in cancer therapy: beyond immunostimulation. J Cancer Metastas Treat. 2018; 4(0): 4.

[37] Lambin P, Theys J, Landuyt W, et al. Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours. Anaerobe. 1998; 4(4): 183-188.

[38] Roussos E, Condeelis J, Patsialou A. Chemotaxis in cancer. Nat Rev Cancer. 2011; 11(8): 573-587.

[39] Irazoki O, Campoy S, Barbé J. The transient multidrug resistance phenotype of Salmonella enterica swarming cells is abolished by sub-inhibitory concentrations of antimicrobial compounds. Front Microbiol. 2017; 8: 1360.

[40] Westerman T, McClelland M, Elfenbein J, YeiE regulates motility and gut colonization in Salmonella enterica serotype Typhimurium. mBio, 2021. 12(3): e0368020.

[41] Hobbs L, Allen L, Bias M, et al. The opposing role of propionate in modulating Listeria monocytogenes intracellular infections. Front Microbiol. 2021; 12: 721801.

[42] Dussurget O, Bierne H, Cossart P. The bacterial pathogen Listeria monocytogenes and the interferon family: type I, type II and type III interferons. Front Cell Infect Microbiol. 2014; 4: 50.

[43] Wood LM, Guirnalda PD, Seavey MM, Paterson Y. Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors. Immunol Res. 2008; 42(1–3): 233-245.

[44] Staedtke V, Gray-Bethke T, Liu G, Liapi E, Riggins GJ, Bai RY. Neutrophil depletion enhanced the Clostridium novyi-NT therapy in mouse and rabbit tumor models. Neurooncol Adv. 2022(1): vdab184.

[45] Sharafabad BE, Abdoli A, Abdolmohammadi Khiav L, Meskini M, Jamur P, Dilmaghani A. Therapeutic potential of Clostridium novyi-NT in cancer: current knowledge and future perspectives. Curr Cancer Drug Targets. 2023; 23(9): 682-696.

[46] Zheng D, Chen Y, Li Z, et al. Optically-controlled bacterial metabolite for cancer therapy. Nat Commun. 2018; 9(1): 1680.

[47] Shi Y, Zheng W, Yang K, et al. Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. J Exp Med. 2020; 5: 217.

[48] Menzfeld C, John M, van Rossum D, et al. Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism. Glia. 2015; 63(6): 1083-1099.

[49] Caruso R, Warner N, Inohara N, Núñez G. NOD1 and NOD2: signaling, host defense, and inflammatory disease. Immunity. 2014; 41(6): 898-908.

[50] Van Dessel N, Swofford C, Forbes N. Potent and tumor specific: arming bacteria with therapeutic proteins. Ther Deliv. 2015; 6(3): 385-399.

[51] Liu Q, Yang Y, Pan M, Yang F, Yu Y, Qian Z. Role of the gut microbiota in tumorigenesis and treatment. Theranostics. 2024; 14(6): 2304-2328.

[52] Tiwari S, Han Z. Immunotherapy: advancing glioblastoma treatment – a narrative review of scientific studies. Cancer Rep (Hoboken). 2023; 7(2): e1947.

[53] Routy B, Gopalakrishnan V, Daillère R, Zitvogel L, Wargo JA, Kroemer G. The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol. 2018; 15(6): 382-396.

[54] Lin NY, Fukuoka S, Koyama S, et al. Microbiota-driven antitumour immunity mediated by dendritic cell migration. Nature. 2025; 644: 1058–1068.

[55] Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013; 342(6161): 967-970.

[56] Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013; 342(6161): 971-976.

[57] Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018; 359(6371): 97-103.

[58] Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015; 350(6264): 1084-1089.

[59] Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990; 249(4975): 1431-1433.

[60] Overacre-Delgoffe AE, Bumgarner HJ, Cillo AR, et al. Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer. Immunity. 2021; 54(12): 2812-2824.e4.

[61] Park JS, Gazzaniga FS, Wu M, et al. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance. Nature. 2023; 617(7960): 377-385.

[62] Bianchi M. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007; 81(1): 1-5.

[63] Fritz T, Niederreiter L, Adolph T, Blumberg RS, Kaser A. Crohn's disease: NOD2, autophagy and ER stress converge. Gut. 2011; 60(11): 1580-1588.

[64] Takashima K, Matsunaga N, Yoshimatsu M, et al. Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br J Pharmacol. 2009; 157(7): 1250-1262.

[65] Baldwin A. THE NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996; 14(14): 649-681.

[66] Khalaf JK, Bowen WS, Bazin HG, et al. Characterization of TRIF selectivity in the AGP class of lipid A mimetics: role of secondary lipid chains. Bioorg Med Chem Lett. 2015; 25(3): 547-553.

[67] Kaczorowski D, Nakao A, McCurry K, Billiar T. Toll-like receptors and myocardial ischemia/reperfusion, inflammation, and injury. Curr Cardiol Rev. 2009; 5(3): 196-202.

[68] Yoon SI, Kurnasov O, Natarajan V, et al. Structural basis of TLR5-flagellin recognition and signaling. Science (Washington, D.C.), 2012; 335: 859-864.

[69] Rhee SH, Kim H, Moyer MP, Pothoulakis C. Role of MyD88 in phosphatidylinositol 3-kinase activation by flagellin/toll-like receptor 5 engagement in colonic epithelial cells. J Biol Chem. 2006; 281(27): 18560-18568.

[70] Bao W, Wang Y, Fu Y, et al. mTORC1 regulates flagellin-induced inflammatory response in macrophages. PLoS ONE. 2015; 10(5): e0125910.

[71] Halff EF, Diebolder CA, Versteeg M, Schouten A, Brondijk TC, Huizinga EG. Formation and structure of a NAIP5-NLRC4 inflammasome induced by direct interactions with conserved N- and C-terminal regions of flagellin. J Biol Chem. 2012; 287(46): 38460-38472.

[72] Paidimuddala B, Cao J, Zhang L. Structural basis for flagellin-induced NAIP5 activation. Sci Adv. 2023; 9(49): eadi8539.

[73] Krieg A, Correa RG, Garrison JB, et al. XIAP mediates NOD signaling via interaction with RIP2. Proc Natl Acad Sci USA. 2009; 106(34): 14524-14529.

[74] Groeger S, Meyle J. Oral mucosal epithelial cells. Front Immunol. 2019; 10: 208.

[75] Watanabe Y, Nagai Y, Takatsu K. Activation and regulation of the pattern recognition receptors in obesity-induced adipose tissue inflammation and insulin resistance. Nutrients. 2013; 5(9): 3757-3778.

[76] He W, Qu T, Yu Q, et al. LPS induces IL-8 expression through TLR4, MyD88, NF-kappaB and MAPK pathways in human dental pulp stem cells. Int Endod J. 2013; 46(2): 128-136.

[77] Byrd-Leifer C, Block E, Takeda K, Akira S, Ding A. The role of MyD88 and TLR4 in the LPS-mimetic activity of taxol. Eur J Immunol. 2001; 31(8): 2448-2457.

[78] Odendall C, Kagan J. Host-encoded sensors of bacteria: our windows into the microbial world. Microbiol Spectr. 2019; 7(3): 10.1128.

[79] Hovden A, Karlsen M, Jonsson R, Appel S. The bacterial preparation OK432 induces IL-12p70 secretion in human dendritic cells in a TLR3 dependent manner. PLoS ONE. 2012; 7(2): e31217.

[80] Granucci F, Feau S, Zanoni I, et al. The immune response is initiated by dendritic cells via interaction with microorganisms and interleukin-2 production. J Infect Dis. 2003; 187(suppl 2): S346-S350.

[81] Wang S, Deng S, Cao Y, et al. Overexpression of toll-like receptor 4 contributes to phagocytosis of Salmonella enterica serovar Typhimurium via phosphoinositide 3-kinase signaling in sheep. Cell Physiol Biochem. 2018; 49(2): 662-677.

[82] Pangilinan C, Lee C. Salmonella-based targeted cancer therapy: updates on a promising and innovative tumor immunotherapeutic strategy. Biomedicines. 2019; 7(2): 36.

[83] Phan TX, Nguyen VH, Duong MT, Hong Y, Choy HE, Min J. Activation of inflammasome by attenuated Salmonella typhimurium in bacteria-mediated cancer therapy. Microbiol Immunol. 2015; 59(11): 664-675.

[84] Chang Z, Guo X, Li X, et al. Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization. Cell. 2025; 188(7): 1842-1857.

[85] Gurbatri C, Arpaia N, Danino T. Engineering bacteria as interactive cancer therapies. Science. 2022; 378(6622): 858-864.

[86] Jiang S, Phan TX, Nam T, et al. Inhibition of tumor growth and metastasis by a combination of Escherichia coli-mediated cytolytic therapy and radiotherapy. Mol Ther. 2010; 18(3): 635-642.

[87] Kim SH, Castro F, Paterson Y, Gravekamp C. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res. 2009; 69(14): 5860-5866.

[88] Brynildsen MP, Winkler JA, Spina CS, MacDonald IC, Collins JJ. Potentiating antibacterial activity by predictably enhancing endogenous microbial ROS production. Nat Biotechnol. 2013; 31(2): 160-165.

[89] Taylor BN, Mehta RR, Yamada T, et al. Noncationic peptides obtained from azurin preferentially enter cancer cells. Cancer Res. 2009; 69(2): 537-546.

[90] Yamada T, Goto M, Punj V, et al. Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer. Proc Natl Acad Sci USA. 2002; 99(22): 14098-14103.

[91] Chaudhari A, Mahfouz M, Fialho AM, et al. Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth. Biochemistry. 2007; 46(7): 1799-1810.

[92] Xia C, Cai Y, Ren S, Xia C. Role of microbes in colorectal cancer therapy: cross-talk between the microbiome and tumor microenvironment. Front Pharmacol. 2022; 13: 1051330.

[93] Lynch J, Goers L, Lesser C. Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics. Trends Pharmacol Sci. 2022; 43(9): 772-786.

[94] Tang H, Zhou T, Jin W, et al. Tumor-targeting engineered probiotic Escherichia coli Nissle 1917 inhibits colorectal tumorigenesis and modulates gut microbiota homeostasis in mice. Life Sci. 2023; 324: 121709.

[95] Yu X, Lin C, Yu J, Qi Q, Wang Q. Bioengineered Escherichia coli Nissle 1917 for tumour-targeting therapy. Microb Biotechnol. 2020; 13(3): 629-636.

[96] Felgner S, Frahm M, Kocijancic D, et al. aroA-deficient Salmonella enterica serovar Typhimurium is more than a metabolically attenuated mutant. mBio. 2016; 7(5): e01220-16.

[97] Zhi Y, Lin SM, Jang A, et al. Effective mucosal live attenuated Salmonella vaccine by deleting phosphotransferase system component genes ptsI and crr. J Microbiol. 2019; 57(1): 64-73.

[98] Yu B, Yang M, Shi L, et al. Explicit hypoxia targeting with tumor suppression by creating an “obligate” anaerobic Salmonella Typhimurium strain. Sci Rep. 2012; 2(1): 436.

[99] Geiger R, Rieckmann JC, Wolf T, et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. 2016; 167(3): 829-842.e13.

[100] Canale FP, Basso C, Antonini G, et al. Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature. 2021; 598(7882): 662-666.

[101] Chiang C, Hong Y. In situ delivery of biobutyrate by probiotic Escherichia coli for cancer therapy. Sci Rep. 2021; 11(1): 18172.

[102] Shi H, Chen L, Liu Y, et al. Bacteria-driven tumor microenvironment-sensitive nanoparticles targeting hypoxic regions enhances the chemotherapy outcome of lung cancer. Int J Nanomed. 2023; 18: 1299-1315.

[103] Xie S, Chen M, Song X, et al. Bacterial microbots for acid-labile release of hybrid micelles to promote the synergistic antitumor efficacy. Acta Biomater. 2018; 78: 198-210.

[104] Zhang Y, Xue X, Fang M, et al. Upconversion optogenetic engineered bacteria system for time-resolved imaging diagnosis and light-controlled cancer therapy. ACS Appl Mater Interfaces. 2022; 14(41): 46351-46361.

[105] Newman JD, Chopra J, Shah P, et al. Amino acid divergence in the ligand-binding pocket of Vibrio LuxR/HapR proteins determines the efficacy of thiophenesulfonamide inhibitors. Mol Microbiol. 2021; 116(4): 1173-1188.

[106] Dai Y, Toley BJ, Swofford CA, Forbes NS. Construction of an inducible cell-communication system that amplifies Salmonella gene expression in tumor tissue. Biotechnol Bioeng. 2013; 110(6): 1769-1781.

[107] Fairfield B, Schnabl B. Gut dysbiosis as a driver in alcohol-induced liver injury. JHEP Rep. 2021; 3(2): 100220.

[108] Nguyen VD, Han J, Choi YJ, et al. Active tumor-therapeutic liposomal bacteriobot combining a drug (paclitaxel)-encapsulated liposome with targeting bacteria (Salmonella Typhimurium). Sens Actuators, B. 2016; 224: 217-224.

[109] Xie S, Zhao L, Song X, Tang M, Mo C, Li X. Doxorubicin-conjugated Escherichia coli Nissle 1917 swimmers to achieve tumor targeting and responsive drug release. J Control Release. 2017; 268: 390-399.

[110] Wu D, Zhao Z, Liu H, et al. Escherichia coli Nissle 1917-driven microrobots for effective tumor targeted drug delivery and tumor regression. Acta Biomater. 2023; 169: 477-488.

[111] Moammeri A, Chegeni MM, Sahrayi H, et al. Current advances in niosomes applications for drug delivery and cancer treatment. Mater Today Biol; 2023: 100837.

[112] Zhu X, Chen S, Hu X, et al. Near-infrared nano-optogenetic activation of cancer immunotherapy via engineered bacteria. Adv Mater. 2023; 35(8): e2207198.

[113] Tan WS, Hall E, Kamat AM, Kelly JD. Clinical trial design for non-muscle-invasive bladder cancer. Nat Rev Urol. 2023; 20(10): 575-576.

[114] Singh B, Sims H, Trueheart I, et al. A phase I clinical trial to assess safety and tolerability of injectable collagenase in women with symptomatic uterine fibroids. Reprod Sci. 2021; 28(9): 2699-2709.

[115] Cunningham C, Nemunaitis J. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: cL-017. Version: April 9, 2001. Hum Gene Ther. 2001; 12(12): 1594-1596.

[116] Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol; 20(1): 142-152.

[117] Heimann D, Rosenberg S. Continuous intravenous administration of live genetically modified Salmonella typhimurium in patients with metastatic melanoma. J Immunother. 2003; 26(2): 179-180.

[118] Gniadek TJ, Augustin L, Schottel J, et al. A phase I, dose escalation, single dose trial of oral attenuated Salmonella typhimurium containing human IL-2 in patients with metastatic gastrointestinal cancers. J Immunother. 2020; 43(7): 217-221.

[119] Schmitz-Winnenthal FH, Grenacher L, Friedrich T, et al. VXM01, an oral T-cell vaccine targeting the tumor vasculature: results from a randomized, controlled, first-in-man study in pancreatic cancer patients. J Clin Oncol. 2013; 31(15_suppl): 3090-3090.

[120] Wick W, Wick A, Chinot OL, et al. Oral DNA vaccination targeting VEGFR2 combined with anti-PDL1 avelumab in patients with progressive glioblastoma: safety run-in results—NCT03750071. J Clin Oncol. 2020; 38(15_suppl): 3001-3001.

[121] Galicia-Carmona T, Arango-Bravo E, Serrano-Olvera JA, et al. ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer. Hum Vaccin Immunother. 2021; 17(8): 2617-2625.

[122] Huh WK, Brady WE, Moore KN, et al. A phase 2 study of live-attenuated Listeria monocytogenes cancer immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265). J Clin Oncol. 2014; 32(15_suppl): TPS5617-TPS5617.

[123] Eng C, Fakih M, Amin M, et al. A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. Oncotarget. 2020; 11(15): 1334-1343.

[124] Le DT, Wang-Gillam A, Picozzi V, et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015; 33(12): 1325-1333.

[125] Le DT, Brockstedt DG, Nir-Paz R, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2012; 18(3): 858-868.

[126] Mohamed MB, Ali MH, Shamaa MA, Shaaban SM. Single course of intravesical Bacillus Calmette-Guerin versus single course with maintenance therapy in the management of nonmuscle invasive bladder cancer: a prospective randomized study. Urol Ann. 2020; 12(4): 360-365.

[127] Boban T, Milić Roje B, Knezović D, et al. Urinary microbiota changes among NMIBC patients during BCG therapy: comparing BCG responders and non-responders. Front Cell Infect Microbiol. 2025; 15: 2025.

[128] Liu K, Wang L, Peng J, et al. Drug-loaded Bacillus Calmette-Guérin bacteria for immuno-chemo combo therapy in bladder cancer. Adv Mater. 2024; 36(19): e2310735.

[129] Staedtke V, Roberts NJ, Bai RY, Zhou S. Clostridium novyi-NT in cancer therapy. Genes Dis. 2016; 3(2): 144-152.

[130] Feng X, He P, Zeng C, et al. Novel insights into the role of Clostridium novyi-NT related combination bacteriolytic therapy in solid tumors. Oncol Lett. 2021; 21(2): 110.

[131] Tomita Y, Goto Y, Sakata S, et al. Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors. Oncoimmunology. 2022; 11(1): 2081010.

[132] Derosa L, Zitvogel L. A probiotic supplement boosts response to cancer immunotherapy. Nat Med. 2022; 28(4): 633-634.

[133] Zheng D, Li R, An J, et al. Prebiotics-encapsulated probiotic spores regulate gut microbiota and suppress colon cancer. Adv Mater. 2020; 32(45): e2004529.

[134] Gabrielson A, Spitz J, Hellstrom W. Collagenase Clostridium histolyticum in the treatment of urologic disease: current and future impact. Sex Med Rev. 2018; 6(1): 143-156.

[135] Leventhal DS, Sokolovska A, Li N, et al. Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat Commun. 2020; 11(1): 2739.

[136] Luke JJ, Piha-Paul SA, Medina T, et al. Phase I study of SYNB1891, an engineered E. coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies. Clin Cancer Res. 2023; 29(13): 2435-2444.

[137] Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002; 20(1): 142-152.

[138] Lin Z, Meng F, Ma Y, et al. In situ immunomodulation of tumors with biosynthetic bacteria promote anti-tumor immunity. Bioact Mater. 2024; 32: 12-27.

[139] Low KB, Ittensohn M, Le T, et al. Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo. Nat Biotechnol. 1999; 17(1): 37-41.

[140] Nemunaitis J, Cunningham C, Senzer N, et al. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 2003; 10(10): 737-744.

[141] Kondapuram SK, Ramachandran HK, Arya H, Coumar MS. Targeting survivin for cancer therapy: strategies, small molecule inhibitors and vaccine based therapeutics in development. Life Sci. 2023; 335: 122260.

[142] Wallecha A, French C, Petit R, Singh R, Amin A, Rothman J. Lm-LLO-based immunotherapies and HPV-associated disease. J Oncol. 2012; 2012: 542851.

[143] Huh WK, Brady WE, Fracasso PM, et al. Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: an NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2020; 158(3): 562-569.

[144] Wood L, Paterson Y. Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Front Cell Infect Microbiol. 2014; 4: 00051.

[145] Eng C, Fakih M, Amin M, et al. A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. Oncotarget. 2020; 11(15): 1334-1343.

[146] Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol. 2012; 13(7): e301-10.

[147] Le DT, Wang-Gillam A, Picozzi V, et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015; 33(12): 1325-1333.

[148] Hassan R, Alley E, Kindler H, et al. Clinical response of live-attenuated, Listeria monocytogenes expressing mesothelin (CRS-207) with chemotherapy in patients with malignant pleural mesothelioma. Clin Cancer Res. 2019; 25(19): 5787-5798.

[149] Jiang S, Qin J, Shi L, et al. Association among gestational weight gain, fucosylated human milk oligosaccharides, and breast milk microbiota─an evidence in healthy mothers from Northwest China. J Agric Food Chem. 2024; 72(45): 25135-25145.

[150] Rezaie N, Aghamohammad S, Gholizadeh Khiavi EHA, Pourshafie MR, Talebi M, Rohani M. Comparison of novel native probiotics and paraprobiotics in modulating oxidative stress and inflammation in DSS-induced colitis: implications for enhanced therapeutic strategies in high fat diet. BMC Immunol. 2024; 25(1): 85.

[151] Badgeley A, Anwar H, Modi K, Murphy P, Lakshmikuttyamma A. Effect of probiotics and gut microbiota on anti-cancer drugs: mechanistic perspectives. Biochim Biophys Acta Rev Cancer. 2021; 1875(1): 188494.

[152] Shioya K, Matsumura T, Seki Y, Shimizu H, Nakamura T, Taniguchi S. Potentiated antitumor effects of APS001F/5-FC combined with anti-PD-1 antibody in a CT26 syngeneic mouse model. Biosci Biotechnol Biochem. 2021; 85(2): 324-331.

[153] Stevenson A, Panzica A, Holt A, et al. Host-microbe interactions mediating antitumorigenic effects of MRX0518, a gut microbiota-derived bacterial strain, in breast, renal and lung carcinoma. J Clin Oncol. 36(15_suppl): e15006-e15006.

[154] Lauté-Caly DL, Raftis EJ, Cowie P, et al. The flagellin of candidate live biotherapeutic Enterococcus gallinarum MRx0518 is a potent immunostimulant. Sci Rep. 2019; 9(1): 801.

[155] Pant S, Mulder I, Shah AY, et al. A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy. J Clin Oncol. 2019; 37(15_suppl): TPS2670-TPS2670.

[156] Xu M, Zhou L, Zheng L, et al. Sonodynamic therapy-derived multimodal synergistic cancer therapy. Cancer Lett. 2021; 497: 229-242.

[157] Park Y, Park M, Hyun H. Tumor-targeted squaraine dye for near-infrared fluorescence-guided photodynamic therapy. Int J Mol Sci. 2024; 25(6): 3428.

[158] Yang Z, Zhu Y, Dong Z, et al. Engineering bioluminescent bacteria to boost photodynamic therapy and systemic anti-tumor immunity for synergistic cancer treatment. Biomaterials. 2022; 281: 121332.

[159] Guo Y, Song M, Liu X, et al. Photodynamic therapy-improved oncolytic bacterial immunotherapy with FAP-encoding S. typhimurium. J Controlled Release. 2022; 351: 860-871.

[160] Zhu Z, Liu Q, Zhu K, et al. Aggregation-induced emission photosensitizer/bacteria biohybrids enhance Cerenkov radiation-induced photodynamic therapy by activating anti-tumor immunity for synergistic tumor treatment. Acta Biomater. 2023; 167: 519-533.

[161] Ektate K, Munteanu MC, Ashar H, Malayer J, Ranjan A. Chemo-immunotherapy of colon cancer with focused ultrasound and Salmonella-laden temperature sensitive liposomes (thermobots). Sci Rep. 2018; 8(1): 13062.

[162] Du M, Wang T, Peng W, Feng R, Goh M, Chen Z. Bacteria-driven nanosonosensitizer delivery system for enhanced breast cancer treatment through sonodynamic therapy-induced immunogenic cell death. J Nanobiotechnol. 2024; 22(1): 167.

[163] Yin C, Wang Z, Dai C, et al. Light-triggered photosynthetic engineered bacteria for enhanced-photodynamic therapy by relieving tumor hypoxic microenvironment. Theranostics. 2023; 13(5): 1632-1648.

[164] Lioret V, Bellaye P, Bernhard Y, et al. Cherenkov radiation induced photodynamic therapy—repurposing older photosensitizers, and radionuclides. Photodiagn Photodyn Ther. 2023; 44: 103816.

[165] Ma X, Liang X, Li Y, et al. Modular-designed engineered bacteria for precision tumor immunotherapy via spatiotemporal manipulation by magnetic field. Nat Commun. 2023; 14(1): 1606.

[166] Yang Y, Wang Y, Zeng F, Chen Y, Chen Z, Yan F. Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy. Cell Rep Med. 2024; 5(5): 101512.

[167] Brennan S, Watson DL, Rudd DM, Kandasamy Y. Kidney growth following preterm birth: evaluation with renal parenchyma ultrasonography. Pediatr Res. 2023; 93(5): 1302-1306.

[168] Wang P, Li A, Yu L, Chen Y, Xu D. Energy conversion-based nanotherapy for rheumatoid arthritis treatment. Front Bioeng Biotechnol. 2020; 8: 652.

[169] Chen Q, Liu X, Fan J, et al. Self-mineralized photothermal bacteria hybridizing with mitochondria-targeted metal–organic frameworks for augmenting photothermal tumor therapy. Adv Funct Mater. 2020; 30(14): 1909806.

[170] Yang X, Komatsu S, Reghu S, Miyako E. Optically activatable photosynthetic bacteria-based highly tumor specific immunotheranostics. Nano Today. 2021; 37: 101100.

[171] Chen W, Guo Z, Zhu Y, Qiao N, Zhang Z, Sun X. Combination of bacterial-photothermal therapy with an anti-PD-1 peptide depot for enhanced immunity against advanced cancer. Adv Funct Mater. 2020; 30(1): 1906623.

[172] Chen W, He C, Qiao N, et al. Dual drugs decorated bacteria irradiate deep hypoxic tumor and arouse strong immune responses. Biomaterials. 2022; 286: 121582.

[173] Xie S, Zhang P, Zhang Z, et al. Bacterial navigation for tumor targeting and photothermally-triggered bacterial ghost transformation for spatiotemporal drug release. Acta Biomater. 2021; 131: 172-184.

[174] Wang Y, Wang H, Wei L, Li S, Liu L, Wang X. Synthetic promoter design in Escherichia coli based on a deep generative network. Nucleic Acids Res. 2020; 48(12): 6403-6412.

[175] Zhang P, Wang H, Xu H, et al. Deep flanking sequence engineering for efficient promoter design using DeepSEED. Nat Commun. 2023; 14(1): 6309.

[176] Ren R, Yu H, Teng J, et al. CAPE: a deep learning framework with chaos-attention net for promoter evolution. Brief Bioinform. 2024; 25(5): bbae398.

[177] Zhao C, Guan Y, Yan S, Li J. Exploring the promoter generation and prediction of Halomonas spp. based on GAN and multi-model fusion methods. Int J Mol Sci. 2024; 25(23): 13137.

[178] Yang B, Chen Y, Jiang M. Reverse engineering of gene regulatory networks using flexible neural tree models. Neurocomputing. 2013; 99: 458-466.

[179] Merzbacher C, Mac Aodha O, Oyarzún DA. Bayesian optimization for design of multiscale biological circuits. ACS Synth Biol. 2023; 12(7): 2073-2082.

[180] Saltepe B, Bozkurt EU, Güngen MA, Çiçek AE, Şeker UÖŞ. Genetic circuits combined with machine learning provides fast responding living sensors. Biosens Bioelectron. 2021; 178: 113028.

[181] Wu S, Feng J, Liu C, et al. Machine learning aided construction of the quorum sensing communication network for human gut microbiota. Nat Commun. 2022; 13(1): 3079.

[182] Ashikur Rahman M, Mamun Ali M, Ahmed K, et al. DeepQSP: identification of quorum sensing peptides through neural network model. Results Eng. 2024; 24: 102878.

[183] Lupolova N, Dallman TJ, Holden NJ, Gally DL. Patchy promiscuity: machine learning applied to predict the host specificity of Salmonella enterica and Escherichia coli. Microb Genom. 2017; 3(10): e000135.

[184] Golriz Khatami S, Mubeen S, Bharadhwaj VS, Kodamullil AT, Hofmann-Apitius M, Domingo-Fernández D. Using predictive machine learning models for drug response simulation by calibrating patient-specific pathway signatures. NPJ Syst Biol Applic. 2021; 7(1): 40.

[185] Liu J, Weller GER, Zern B, et al. Computational model for nanocarrier binding to endothelium validated using in vivo, in vitro, and atomic force microscopy experiments. Proc Natl Acad Sci USA. 2010; 107(38): 16530-16535.

[186] Khalid S, Brandner AF, Juraschko N, et al. Computational microbiology of bacteria: advancements in molecular dynamics simulations. Structure. 2023; 31(11): 1320-1327.

[187] Ul Ain N, Naveed M, Aziz T, et al. Mix-match synthesis of nanosynbiotics from probiotics and prebiotics to counter gut dysbiosis via AI integrated formulation profiling. Sci Rep. 2024; 14(1): 18397.

[188] Gurbatri CR, Lia I, Vincent R, et al. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci Transl Med. 2020; 12(530): eaax0876.

[189] Chou W, Chen Q, Yuan L, et al. An artificial intelligence-assisted physiologically-based pharmacokinetic model to predict nanoparticle delivery to tumors in mice. J Control Release. 2023; 361: 53-63.

[190] López-Estévez AM, Lapuhs P, Pineiro-Alonso L, Alonso MJ. Personalized cancer nanomedicine: overcoming biological barriers for intracellular delivery of biopharmaceuticals. Adv Mater. 2024; 36(14): e2309355.

[191] Nguyen D, Chong A, Hong Y, Min J. Bioengineering of bacteria for cancer immunotherapy. Nat Commun. 2023; 14(1): 3553.

[192] Zhu M, Zhuang J, Li Z, et al. Machine-learning-assisted single-vessel analysis of nanoparticle permeability in tumour vasculatures. Nat Nanotechnol. 2023; 18(6): 657-666.

[193] Song D, Zhang X, Li B, et al. Deep learning-assisted automated multidimensional single particle tracking in living cells. Nano Lett. 2024; 24(10): 3082-3088.

[194] Liu Y, Zhou M, Luo D, et al. Bacteria-mediated in vivo delivery of quantum dots into solid tumor. Biochem Biophys Res Commun. 2012; 425(4): 769-774.

[195] Husseini GA, Abdel-Jabbar NM, Mjalli FS, Pitt WG. Modeling and sensitivity analysis of acoustic release of doxorubicin from unstabilized pluronic P105 using an artificial neural network model. Technol Cancer Res Treat. 2007; 6(1): 49-56.

[196] Wagner S, Friedman L, Dodd R. Transfusion-associated bacterial sepsis. Clin Microbiol Rev. 1994; 7(3): 290-302.

[197] Ho C, Jean N, Hogan CA, et al. Rapid identification of pathogenic bacteria using Raman spectroscopy and deep learning. Nat Commun. 2019; 10(1): 4927.

[198] Lee S, Rho M. Multimodal deep learning applied to classify healthy and disease states of human microbiome. Sci Rep. 2022; 12(1): 824.

[199] Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021; 26(1): 80-93.

[200] Tran TTV, Surya Wibowo A, Tayara H, Chong KT. Artificial intelligence in drug toxicity prediction: recent advances, challenges, and future perspectives. J Chem Inf Model. 2023; 63(9): 2628-2643.

[201] Jiménez-Luna J, Grisoni F, Weskamp N, Schneider G. Artificial intelligence in drug discovery: recent advances and future perspectives. Expert Opin Drug Discov. 2021; 16(9): 949-959.

[202] Huang J, Roy R. Multiple-drug hemodynamic control using fuzzy decision theory. IEEE Trans Biomed Eng. 1998; 45(2): 213-228.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.